Description
Osicent 80 mg (Osimertinib):
The epidermal growth factor receptor (EGFR) kinase inhibitor osimertinib binds irreversibly to specific mutant types of EGFR (T790M, L858R, and exon 19 deletion) at a roughly 9-fold increase. In patients whose non-small cell lung cancer (NSCLC) has progresse during or after EGFR tyrosine kinase inhibitor (TKI) therapy and who have metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive NSCLC, as determine by an FDA-approve test, Osicent 80 mg (Osimertinib) should be treat with
What is Osicent 80 mg and how it works:
Osicent 80 mg is advise at a dose of 80 mg once daily, or until the disease progresses or the toxicity becomes intolerable. You can take osimertinib with or without food. Moreover, if a dose of osimertinib is miss, skip the miss dose and take the scheduled dose. Osicent 80 mg (Osimertinib) should be store at room temperature between 20°C and 25°C. Carefully discard medications that are no longer need or have expire. Keep all medications, including 80 mg of Osicent, out of the hands of young people.
Generic Osimertinib 80 mg:
One drug that is mainly use to treat non-small cell lung cancer (NSCLC) is Osicent 80 mg (Osimertinib). It is a member of the group of medications call tyrosine kinase inhibitors (TKIs), which function by preventing the action of a particular protein known as the epidermal growth factor receptor (EGFR). Targeting NSCLC tumors with certain EGFR mutations—like the T790M mutation—that are frequently linked to resistance to other EGFR inhibitors is the exclusive purpose of osimertinib. Osimertinib serves to slow down or stop the proliferation of cancer cells by reducing the action of mutant EGFR, which delays the progression of the disease and improves patient outcomes.
Osimertinib is usually taken orally once daily at a dosage of 80 mg. However, dosage should be establish by a medical professional skill in treating non-small cell lung cancer (NSCLC) as it may differ based on specific patient variables. Fatigue, nausea, rash, and diarrhea are typical adverse effects.
Benefits Osicent 80 mg (Osimertinib):
1. Specific actions
Osicent 80 mg (Osimertinib) is formulated to specifically target and inhibit the T790M mutation in the epidermal growth factor receptor (EGFR). which is often observed in non-small cell lung cancer (NSCLC). Targeted approach helps in efficient management of tumor development and progression.
2. Proficiency in high-level NSCLC
When treating advanced or metastatic non-small cell lung cancer (NSCLC), Osicent 80 mg (Osimertinib) has demonstrated significant efficacy, particularly in patients who have become resistant to previous generation EGFR inhibitors. For these patients, Osicent 80mg increases the overall response rate and progression-free survival.
3. Infiltration of brain metastasis
One of its main advantages is Osicent 80 mg (Osimertinib)’s ability to cross the blood-brain barrier. Enables effective treatment of brain metastases, a frequent consequence of advanced non-small cell lung cancer.
4. Oral administration
Compared to intravenous therapy, Osicent 80 mg (Osimertinib) is more convenient because osicent 80mg is administered orally once daily. This ease of administration improves patients’ quality of life and compliance.
How to order IEB Pharma medicine…?
Ordering our IEB Pharma Medicines is easy. Currently there is no automated ordering system on our website, we offer various options for ordering IEB Pharma Medicines.
WhatsApp: You can send a message by clicking on our WhatsApp button, a customer service representative of ieb Pharma will assist you in placing your order.
Telegram/Messenger/WeChat: If you want to place an order on our Facebook messenger or Telegram or WeChat, then you can easily place an order by clicking on our message option button.
Email: You can message us at [email protected] for details about your order. We answer your call as soon as we can.
Joseph –
trustworthy and good communication . fast shipment and good product
Fin Allen –
The product and the behaviour of the seller was very satisfying.